FKBP51 acts as a biomarker of early metastasis and is related to carmustine sensitivity in human glioma cells.
CONCLUSIONS: We demonstrated that the effects of FKBP51 on BT325 glioma cell proliferation, migration, invasion and BCNU chemosensitization are modulated via the AKT and NF-κB pathways. Furthermore, our findings suggest the potential of FKBP51 as a prognostic glioma biomarker and an indicator of patient response to chemotherapy.
PMID: 32964982 [PubMed - as supplied by publisher]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Brain Tumor | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Glioma | Study | Translocation